Item 8.01 Other Events.
On June 30, 2020, TELA Bio, Inc. (the "Company") announced that it closed its
underwritten public offering (the "Offering") of 3,000,000 shares of the
Company's common stock, par value $0.001 per share (the "Common Stock") at the
public offering price of $16.00 per share. All of the shares in the Offering
were sold by the Company, resulting in $48.0 million of gross proceeds, before
deducting the underwriters' discounts and commissions and other estimated
offering expenses payable by the Company. In addition, the Company has granted
the underwriters a 30-day option to purchase up to 450,000 additional shares of
Common Stock in the Offering.
The Company currently intends to use the net proceeds from the Offering,
together with its existing cash, cash equivalents and short-term investments, to
hire additional sales and marketing personnel and expand marketing activities to
support the ongoing commercialization of its OviTex and OviTex PRS product
lines, to fund product development and research and development activities,
which may include post-market clinical studies and IDE protocol development for
its OviTex PRS products, and for working capital and general corporate purposes.
Jefferies LLC and Piper Sandler & Co. acted as joint book-running managers for
the Offering. Canaccord Genuity LLC acted as lead manager and JMP Securities LLC
acted as co-manager.
The Offering was made pursuant to the Company's effective registration statement
on Form S-1 (Registration No. 333-239386) filed with the Securities and Exchange
Commission (the "SEC") on June 23, 2020 and declared effective by the SEC on
June 25, 2020, and a final prospectus filed with the SEC on June 26, 2020.
On June 25, 2020, the Company issued a press release announcing the pricing of
the Offering, a copy of which is furnished as Exhibit 99.1 to this Current
Report on Form 8-K. A copy of the press release announcing the closing of the
Offering is furnished as Exhibit 99.2 to this Current Report on Form 8-K.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
The following exhibit is being furnished herewith:
Exhibit
No. Document
99.1 Press Release, dated June 25, 2020.
99.2 Press Release, dated June 30, 2020.
© Edgar Online, source Glimpses
TELA BIO, INC. 
